Oragenics, Inc. (OGEN)
NYSEAMERICAN: OGEN · IEX Real-Time Price · USD
1.020
0.00 (0.00%)
At close: Jul 19, 2024, 4:00 PM
1.030
+0.010 (0.98%)
Pre-market: Jul 22, 2024, 6:39 AM EDT
Oragenics Revenue
Oragenics had revenue of $20.63K in the twelve months ending March 31, 2024. In the year 2023, Oragenics had annual revenue of $37.65K.
Revenue (ttm)
$20.63K
Revenue Growth
-84.54%
P/S Ratio
275.94
Revenue / Employee
$4,126
Employees
5
Market Cap
5.69M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 37.65K | -93.87K | -71.37% |
Dec 31, 2022 | 131.52K | 44.53K | 51.20% |
Dec 31, 2021 | 86.99K | - | - |
Dec 31, 2020 | 0 | - | - |
Dec 31, 2019 | 0 | - | - |
Dec 31, 2018 | 0 | - | - |
Dec 31, 2017 | 0 | - | - |
Dec 31, 2016 | 0 | - | - |
Dec 31, 2015 | 0 | - | - |
Dec 31, 2014 | 939.93K | -92.31K | -8.94% |
Dec 31, 2013 | 1.03M | -299.53K | -22.49% |
Dec 31, 2012 | 1.33M | -112.68K | -7.80% |
Dec 31, 2011 | 1.44M | 135.54K | 10.35% |
Dec 31, 2010 | 1.31M | 667.63K | 104.11% |
Dec 31, 2009 | 641.29K | 407.75K | 174.59% |
Dec 31, 2008 | 233.54K | 100.45K | 75.48% |
Dec 31, 2007 | 133.09K | 66.91K | 101.11% |
Dec 31, 2006 | 66.18K | - | - |
Dec 31, 2005 | 0 | - | - |
Dec 31, 2004 | 196.21K | - | - |
Dec 31, 2003 | 0 | - | - |
Dec 31, 2002 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Sonoma Pharmaceuticals | 12.74M |
Biomerica | 5.41M |
TFF Pharmaceuticals | 885.72K |
Titan Pharmaceuticals | 87.00K |
Ainos | -28.44K |
OGEN News
- 24 days ago - Oragenics Develops Automated Intranasal Device for Treating Concussed Patients - GlobeNewsWire
- 25 days ago - Oragenics, Inc. Announces Closing of Public Offering - GlobeNewsWire
- 26 days ago - Oragenics, Inc. Announces Pricing of Public Offering - GlobeNewsWire
- 27 days ago - Oragenics, Inc. Announces Proposed Public Offering - GlobeNewsWire
- 2 months ago - Oragenics Appoints William “Frank” Peacock MD as Chief Clinical Officer - GlobeNewsWire
- 2 months ago - Oragenics, Inc. to Host Webinar Panel on Neurotrauma Medicine - GlobeNewsWire
- 3 months ago - Oragenics, Inc. Announces Notification of Noncompliance with Additional NYSE American Continued Listing Standards - Business Wire
- 3 months ago - Oragenics, Inc. Files 10K and Provides Company Update - Business Wire